Cubic Life Sciences

Cubic Life Sciences is a biopharmaceutical group headquartered in Hong Kong that specializes in the discovery, development, and commercialization of innovative small molecule drugs. The company operates a significant research and development hub in Suzhou, China, through its subsidiary Cubic Biopharma. Its primary therapeutic focus is oncology, with a specific emphasis on modulating the innate immune system via Toll-like receptor (TLR) agonists. The company's lead candidates, including CBP-1008 and CBP-1018, are currently undergoing clinical trials for the treatment of various solid tumors. Cubic Life Sciences maintains a vertically integrated model that encompasses drug discovery, clinical development, and pharmaceutical manufacturing.